Results 1 to 10 of about 8,062 (139)

Synaptic Vesicle Glycoprotein 2A: Features and Functions [PDF]

Frontiers in Neuroscience, 2022
In recent years, the field of neuroimaging dramatically moved forward by means of the expeditious development of specific radioligands of novel targets.
Rachele Rossi, Rachele Rossi, Shokouh Arjmand, Simone Larsen Bærentzen, Simone Larsen Bærentzen, Albert Gjedde, Albert Gjedde, Albert Gjedde, Anne M. Landau, Anne M. Landau   +9 more
doaj   +7 more sources

Positron Emission Computed Tomography Imaging of Synaptic Vesicle Glycoprotein 2A in Alzheimer’s Disease [PDF]

Frontiers in Aging Neuroscience, 2021
Alzheimer’s disease (AD) is the most common neurodegenerative disorder seen in age-dependent dementia. There is currently no effective treatment for AD, which may be attributed in part to lack of a clear underlying mechanism.
Yanyan Kong, Shibo Zhang, Lin Huang, Chencheng Zhang, Fang Xie, Zhengwei Zhang, Qi Huang, Donglang Jiang, Junpeng Li, Weiyan Zhou, Tao Hua, Bomin Sun, Jiao Wang, Yihui Guan   +13 more
doaj   +7 more sources

Detection of Synaptic Vesicle Glycoprotein 2A in Serum Using a Polypyrrole-Functionalized Graphene Oxide Electrochemical Immunosensor [PDF]

Nanomaterials
Early intervention is pivotal for mitigating the progression of Alzheimer’s disease (AD). This study presents an electrochemical immunosensor targeting synaptic vesicle glycoprotein 2A (SV2A) to facilitate early AD diagnosis.
Yonghong Zhao, Le Li, Jiale Tao, Manying Yang, Chen Li, Xiaoqian Zhang, Yang Zhang, Shiguo Sun, Na Zhao   +8 more
doaj   +5 more sources

A missense mutation of the gene encoding synaptic vesicle glycoprotein 2A (SV2A) confers seizure susceptibility by disrupting amygdalar synaptic GABA release [PDF]

Frontiers in Pharmacology, 2016
Synaptic vesicle glycoprotein 2A (SV2A) is specifically expressed in the membranes of synaptic vesicles and modulates action potential-dependent neurotransmitter release. To explore the role of SV2A in the pathogenesis of epileptic disorders, we recently
Kentaro Tokudome, Takahiro Okumura, Ryo Terada, Saki Shimizu, Naofumi Kunisawa, Tomoji Mashimo, Tomoji Mashimo, Tadao Serikawa, Tadao Serikawa, Masashi Sasa, Yukihiro Ohno   +10 more
doaj   +7 more sources

PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging [PDF]

Frontiers in Neuroscience, 2022
The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A) allowed for the in vivo detection of synaptic density changes, which are correlated with the progression and severity of a variety of neuropsychiatric diseases. While
Takuya Toyonaga, Arman Fesharaki-Zadeh, Arman Fesharaki-Zadeh, Stephen M. Strittmatter, Stephen M. Strittmatter, Richard E. Carson, Zhengxin Cai   +6 more
doaj   +5 more sources

Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J [PDF]

EJNMMI Research, 2020
The ability to quantify synaptic density in vivo in human adults and adolescents is of vital importance to understanding neuropsychiatric disorders.
Jason Bini, Daniel Holden, Kathryn Fontaine, Tim Mulnix, Yihuan Lu, David Matuskey, Jim Ropchan, Nabeel Nabulsi, Yiyun Huang, Richard E. Carson   +9 more
doaj   +5 more sources

Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16 [PDF]

Frontiers in Neurology, 2023
IntroductionSynapse loss is one of the hallmarks of Alzheimer's disease (AD) and is associated with cognitive decline. In this study, we tested [18F]SDM-16, a novel metabolically stable SV2A PET imaging probe, in the transgenic APPswe/PS1dE9 (APP/PS1 ...
Chao Zheng, Takuya Toyonaga, Baosheng Chen, LaShae Nicholson, William Mennie, Michael Liu, Joshua Spurrier, Kristin Deluca, Stephen M. Strittmatter, Richard E. Carson, Yiyun Huang, Zhengxin Cai   +11 more
doaj   +4 more sources

Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer’s Disease Patients [PDF]

Frontiers in Cellular Neuroscience, 2019
Sections from the middle frontal gyrus (Brodmann area 46) of autopsy-confirmed Alzheimer’s disease (AD) patients and non-demented subjects were examined for the prevalence of hallmark AD pathology, including amyloid-β (Aβ) plaques, phosphorylated tau ...
Athanasios Metaxas, Camilla Thygesen, Sanne R. R. Briting, Anne M. Landau, Anne M. Landau, Sultan Darvesh, Sultan Darvesh, Bente Finsen   +7 more
doaj   +8 more sources

Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE) [PDF]

Molecular Brain, 2022
Synaptic vesicle glycoprotein-2 (SV2) is a family of proteins consisting of SV2A, SV2B, and SV2C. This protein family has attracted attention in recent years after SV2A was shown to be an epileptic drug target and a perhaps a biomarker of synaptic ...
Burcu A. Pazarlar, Sanjay S. Aripaka, Viktor Petukhov, Lars Pinborg, Konstantin Khodosevich, Jens D. Mikkelsen   +5 more
doaj   +2 more sources

Sleep deprivation increases levels of the synaptic density marker SV2A in the human brain. [PDF]

PLoS Biology
Sleep is essential for synaptic homeostasis, a proposed mechanism whereby wakefulness leads to synaptic potentiation and sleep facilitates synaptic down-selection.
David Elmenhorst, Anna L Foerges, Ali Gordji-Nejad, Eva-Maria Elmenhorst, Tina Kroll, Andreas Matusch, Simone Beer, Bernd Neumaier, Philipp Krapf, Christoph Lerche, Alexander Drzezga, Andreas Bauer   +11 more
doaj   +2 more sources